Small molecule · Inhibitor of extracellular signal-regulated kinase 1 (ERK1) (MAPK3) and extracellular signal-regulated kinase 2 (ERK2) (MAPK1) · developed by Kura Oncology
Edaxeterkib (KO-947) is an intravenously administered small-molecule inhibitor that binds and inhibits ERK1 and ERK2, blocking MAPK/ERK-mediated signal transduction. It is being studied in advanced malignant neoplasms.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03051035 | Phase 1 | Advanced Malignant Neoplasm | Terminated | KURA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Malignant Neoplasm
Updated Oct 18, 2026. Something wrong or missing? Report it on the KURA page.
See KURA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KURA catalysts and pipeline →